Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
Despite the availability of molecularly targeted agents for advanced hepatocellular carcinoma (aHCC), these are limited to compensated cirrhotic patients, and concerns about decreased hepatic functional reserve (HFR) and unknown adverse events, which may affect long-term survival, remain unaddressed...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/4/629 |
| _version_ | 1797413416598503424 |
|---|---|
| author | Kei Moriya Tadashi Namisaki Hiroaki Takaya Kosuke Kaji Hideto Kawaratani Naotaka Shimozato Yasuhiko Sawada Akitoshi Douhara Shinya Sato Masanori Furukawa Koh Kitagawa Takemi Akahane Hitoshi Yoshiji |
| author_facet | Kei Moriya Tadashi Namisaki Hiroaki Takaya Kosuke Kaji Hideto Kawaratani Naotaka Shimozato Yasuhiko Sawada Akitoshi Douhara Shinya Sato Masanori Furukawa Koh Kitagawa Takemi Akahane Hitoshi Yoshiji |
| author_sort | Kei Moriya |
| collection | DOAJ |
| description | Despite the availability of molecularly targeted agents for advanced hepatocellular carcinoma (aHCC), these are limited to compensated cirrhotic patients, and concerns about decreased hepatic functional reserve (HFR) and unknown adverse events, which may affect long-term survival, remain unaddressed. In this study, we enrolled 96 aHCC patients treated with bimonthly hepatic arterial infusion chemotherapy (B-HAIC) with cisplatin or sorafenib monotherapy (oral sorafenib 400 mg twice daily) not only to demonstrate its efficacy and significance but also to indicate preferable candidates by setting a response-related biomarker. Differences in treatment had no significant effect on overall survival (OS). The response rate in patients treated with B-HAIC was relatively higher than those treated with sorafenib. HFR was well maintained over the treatment course with B-HAIC, while it was significantly impaired with sorafenib. By employing multivariate analysis, we found negative trends between progression-free survival (PFS) periods and serum levels of alpha fetoprotein as well as des-gamma-carboxy prothrombin (DCP). In addition, a logistic regression analysis of the relationship between serum DCP levels and PFS periods over 420 days (14 months) showed that the PFS periods of patients with higher DCP was significantly shorter than those of patients with lower DCP (<i>p</i> = 0.02). Subsequently, the present study demonstrated the efficacy and safety of B-HAIC and identified a predictor of unpreferable patients. Based on these results, B-HAIC might be an alternative treatment after the implementation of new molecularly targeted therapies. |
| first_indexed | 2024-03-09T05:17:33Z |
| format | Article |
| id | doaj.art-d572db5c20ff439fa2a8d423b0a02982 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T05:17:33Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d572db5c20ff439fa2a8d423b0a029822023-12-03T12:44:26ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-0110462910.3390/jcm10040629Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion ChemotherapyKei Moriya0Tadashi Namisaki1Hiroaki Takaya2Kosuke Kaji3Hideto Kawaratani4Naotaka Shimozato5Yasuhiko Sawada6Akitoshi Douhara7Shinya Sato8Masanori Furukawa9Koh Kitagawa10Takemi Akahane11Hitoshi Yoshiji12Department of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDepartment of Gastroenterology and Hepatology, Nara Medical University, Nara 634-8521, JapanDespite the availability of molecularly targeted agents for advanced hepatocellular carcinoma (aHCC), these are limited to compensated cirrhotic patients, and concerns about decreased hepatic functional reserve (HFR) and unknown adverse events, which may affect long-term survival, remain unaddressed. In this study, we enrolled 96 aHCC patients treated with bimonthly hepatic arterial infusion chemotherapy (B-HAIC) with cisplatin or sorafenib monotherapy (oral sorafenib 400 mg twice daily) not only to demonstrate its efficacy and significance but also to indicate preferable candidates by setting a response-related biomarker. Differences in treatment had no significant effect on overall survival (OS). The response rate in patients treated with B-HAIC was relatively higher than those treated with sorafenib. HFR was well maintained over the treatment course with B-HAIC, while it was significantly impaired with sorafenib. By employing multivariate analysis, we found negative trends between progression-free survival (PFS) periods and serum levels of alpha fetoprotein as well as des-gamma-carboxy prothrombin (DCP). In addition, a logistic regression analysis of the relationship between serum DCP levels and PFS periods over 420 days (14 months) showed that the PFS periods of patients with higher DCP was significantly shorter than those of patients with lower DCP (<i>p</i> = 0.02). Subsequently, the present study demonstrated the efficacy and safety of B-HAIC and identified a predictor of unpreferable patients. Based on these results, B-HAIC might be an alternative treatment after the implementation of new molecularly targeted therapies.https://www.mdpi.com/2077-0383/10/4/629hepatocellular carcinomahepatic arterial infusion chemotherapymolecularly targeted therapieshepatic functional reservedes-gamma-carboxy prothrombin |
| spellingShingle | Kei Moriya Tadashi Namisaki Hiroaki Takaya Kosuke Kaji Hideto Kawaratani Naotaka Shimozato Yasuhiko Sawada Akitoshi Douhara Shinya Sato Masanori Furukawa Koh Kitagawa Takemi Akahane Hitoshi Yoshiji Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy Journal of Clinical Medicine hepatocellular carcinoma hepatic arterial infusion chemotherapy molecularly targeted therapies hepatic functional reserve des-gamma-carboxy prothrombin |
| title | Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy |
| title_full | Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy |
| title_fullStr | Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy |
| title_full_unstemmed | Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy |
| title_short | Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy |
| title_sort | identification of the response related biomarker of bimonthly hepatic arterial infusion chemotherapy |
| topic | hepatocellular carcinoma hepatic arterial infusion chemotherapy molecularly targeted therapies hepatic functional reserve des-gamma-carboxy prothrombin |
| url | https://www.mdpi.com/2077-0383/10/4/629 |
| work_keys_str_mv | AT keimoriya identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT tadashinamisaki identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT hiroakitakaya identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT kosukekaji identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT hidetokawaratani identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT naotakashimozato identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT yasuhikosawada identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT akitoshidouhara identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT shinyasato identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT masanorifurukawa identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT kohkitagawa identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT takemiakahane identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy AT hitoshiyoshiji identificationoftheresponserelatedbiomarkerofbimonthlyhepaticarterialinfusionchemotherapy |